同和药业：公司阿戈美拉汀、奥吡卡朋原料药获得韩国市场准入资格 智通财经7月22日电，同和药业(300636.SZ)公告称，公司近日收到韩国食品药品安全部颁发的阿戈美拉 汀、奥吡卡朋药品注册证书。这标志着公司阿戈美拉汀、奥吡卡朋原料药获得了韩国市场的准入资格， 将对公司进一步扩大国际市场业务起到积极作用。 ...

同和药业（300636）公告，近日收到韩国食品药品安全部(MFDS)颁发的阿戈美拉汀、奥吡卡朋药品注 册证书。其中，阿戈美拉汀适用于治疗成人抑郁症，奥吡卡朋是一种COMT抑制剂，临床主要用于治疗 帕金森病和帕金森综合征。公司阿戈美拉汀、奥吡卡朋原料药获得了韩国市场的准入资格，将对公司进 一步扩大国际市场业务起到积极作用。 ...

完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第四次会议审议通过了《关于 2022 年限制性 股票激励计划首次授予部分第三个限售期解除限售条件未成就及回 购注销部分限制性股票的议案》，鉴于公司 2022 年限制性股票激励计 划部分激励对象离职及首次授予部分、暂缓授予部分第三个解除限售 期解除限售条件未成就，同意根据《江西同和药业股份有限公司 2022 年限制性股票激励计划》的相关规定回购注销前述所涉激励对象已获 授但未解除限售的合计 1,575,855 股限制性股票。回购注销完成后， 公司总股本由 42,152.7350 万股变更为 41,995.1495 万股，注册资本 由 42,152.7350 万 元 变 更 为 41,995.1495 万 元 ， 投 资 总 额 由 42,152.7350 万元变更为 41,995.1495 万元。 公司于 2025 年 5 月 16 日召开了 2024 年年度股东大会，审议通 过了《关于 2022 年限制性股票激励计划首次授予部分第三个限售期 解除限售条件未成就及回购注销部分 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-038 江西同和药业股份有限公司 关于公司获得韩国药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到韩 国食品药品安全部（MFDS）颁发的阿戈美拉汀、奥吡卡朋药品注册证 书，相关信息如下： 1、阿戈美拉汀药品注册证书 生产商名称：江西同和药业股份有限公司 生产商地址：江西省奉新高新技术产业园区 2、奥吡卡朋药品注册证书 生产商名称：江西同和药业股份有限公司 生产商地址：江西省奉新高新技术产业园区 认证范围：奥吡卡朋原料药 证书编号：2025-A1-1644 签发日期：2025.07.17 阿戈美拉汀适用于治疗成人抑郁症。 认证范围：阿戈美拉汀原料药 证书编号： 2025-A1-1548 签发日期：2025.07.02 公司进一步扩大国际市场业务起到积极作用。由于医药行业的特点， 相关产品在国际市场的销售情况易受到市场环境变化、汇率波动等因 素影响，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 江西同和药业股份有限公司 ...

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

Market Overview - The Shanghai Composite Index closed at 3525.40 points, above the annual line, with a change of 0.43% [1] - The total trading volume of A-shares reached 987.43 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.51% - Ruisheng Technology (688090) with a deviation rate of 2.05% [1] Stocks with Significant Deviation Rates - The stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, trading at 76.99 yuan - Tongyi Co., Ltd.: 2.50% increase, trading at 16.00 yuan - Ruisheng Technology: 3.24% increase, trading at 35.10 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Qianjiang Motorcycle, Jiuquan Technology, and Huadian International, which have just reached the annual line [1]

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualing Pharmaceutical-B, and others [2]. Core Insights - The report emphasizes the broad market for lipid-lowering treatments, particularly focusing on the competitive landscape of PCSK9-targeted drugs, with approximately 500 million adults in China suffering from dyslipidemia, including 120 million with high cholesterol [3][15]. - The pharmaceutical sector saw a 1.60% increase this week, underperforming the CSI 300 index by 0.35 percentage points, with sub-sectors like medical infrastructure and life sciences performing better than generics and innovative drugs [4][31]. Summary by Sections 1. Industry Perspective and Investment Recommendations - The lipid-lowering market is vast, with intense competition in PCSK9-targeted drugs [15]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market [4][31]. 2. Pharmaceutical Sector Performance - The pharmaceutical sector's performance was mixed, with medical infrastructure and life sciences leading, while generics and innovative drugs lagged [4][37]. - The overall P/E ratio for the pharmaceutical industry is 27.69, with a premium of 35.26% compared to the broader A-share market [37]. 3. Company Dynamics - Notable company announcements include Baiyoutai's licensing agreement for BAT2406 in Latin America and Yifan Pharmaceutical's approval for clinical trials of a growth hormone injection [38][40]. - Companies like WuXi AppTec and Lijun Group have made significant moves, including share buybacks and new product approvals [39][41]. 4. Industry Trends - The report highlights the upcoming patent expirations for major small molecule drugs, which could lead to increased demand for raw materials [5][32]. - The report also notes the expected recovery in overseas demand, which may improve the performance of CXO companies [34]. 5. Research and Development Focus - The report discusses the clinical progress of various PCSK9-targeted therapies, including monoclonal antibodies and gene editing approaches, indicating a strong pipeline in this area [3][23][25]. - The competitive landscape for PCSK9 drugs in China is characterized by pricing and adherence challenges, with several products already on the market [27].

Group 1 - The core viewpoint of the announcement is the approval of the 2024 profit distribution plan by the shareholders' meeting, which includes a cash dividend of 0.4 yuan per 10 shares [1][2] - The profit distribution plan will be implemented within two months after the shareholders' meeting, with the record date set for June 26, 2025 [2][3] - The cash dividends will be directly credited to shareholders' accounts through their securities companies on June 27, 2025 [3][4] Group 2 - The distribution plan specifies that the total share capital will be adjusted if there are changes due to stock buybacks or other factors, maintaining the dividend distribution ratio [1][2] - Different tax rates will apply to individual and institutional investors based on their holding periods, with specific tax obligations outlined for different categories of shares [2] - The announcement includes contact information for inquiries, indicating the company's commitment to transparency and shareholder communication [3][4]

证券代码：300636 证券简称：同和药业 公告编号：2025-037 江西同和药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"或"同和药 业"）于2025年5月16日召开2024年年度股东大会，审议通过了《关 于<公司2024年度利润分配预案>的议案》。现将权益分派事宜公告 如下： 自上述分配方案披露至实施期间，公司总股本因回购注销部分 限制性股票发生变化，由421,527,350股（2025年4月25日）变为 419,951,495股（2025年6月5日）。 本次实施的权益分派方案及其调整原则与公司2024年年度股东 大会审议通过的《关于<公司2024年度利润分配预案>的议案》一 致。 本次权益分派在距离股东大会审议通过分配方案后两个月以内 1/ 3 实施。 二、本次实施的权益分派方案 公 司 2024 年 年 度 权 益 分 派 方 案 为 ： 以 公 司 现 有 总 股 本 419,951,495股为基数，每10股派0.4元现金红利[含税；扣税后，QFII、 ...

Group 1: Impact of Tariffs and Sales Distribution - The company's direct exports to the U.S. are low, so the impact of U.S. tariffs on raw material exports is minimal [1] - Domestic sales account for nearly 20% of total revenue; high-end markets contribute approximately 60% to overseas sales, while emerging markets account for around 20% [1] Group 2: Future Product Potential and Profit Margins - High-potential new products include Rivaroxaban, Apixaban, Empagliflozin, Canagliflozin, Vildagliptin, Febuxostat, and Azilsartan [2] - An improvement in gross margin is expected in the upcoming quarters compared to Q1 [2] Group 3: Depreciation and Raw Material Sales - Two new workshops in the second phase of the second plant will start depreciation after process validation in 2026, with an estimated annual depreciation of around 10 million [2] - Raw materials typically account for about 10% of the sales revenue from generic drug formulations [2] Group 4: Supplier Selection and Competitive Advantage - Generic drug companies usually start looking for qualified raw material suppliers 6-7 years before patent expiration; the company often initiates projects 10 years in advance [2] - The company has established a strong reputation and competitive edge through rigorous quality management and successful audits in high-end markets [2] Group 5: Pricing Trends and Investment - More than half of mature product prices have stabilized, with some still declining but at a reduced rate; raw material capacity is being cleared, preventing long-term price drops [3] - The investment in Boya Biotech focuses on developing high-difficulty specialty formulations, which have high industry entry barriers [3]